Sunshine Net Debt from 2010 to 2024

SBFMW Stock

USD 0.17 0.04 19.05%

Sunshine Biopharma Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2024. Net Debt is the total debt of Sunshine Biopharma Warrant minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2007-09-30

Previous Quarter

-10.9 M

Current Value

-11.7 M

Quarterly Volatility

9.1 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.

Check out the analysis of Sunshine Biopharma Correlation against competitors.

For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Net Debt Growth Pattern

Below is the plot of the Net Debt of Sunshine Biopharma Warrant over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Sunshine Biopharma's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Sunshine Net Debt Regression Statistics

	Arithmetic Mean	(2,907,528)
	Geometric Mean	480,479
	Coefficient Of Variation	(234.38)
	Mean Deviation	5,242,290
	Median	(14,895)
	Standard Deviation	6,814,798
	Sample Variance	46.4T
	Range	18.6M
	R-Value	(0.66)
	Mean Square Error	27.9T
	R-Squared	0.44
	Significance	0.01
	Slope	(1,012,992)
	Total Sum of Squares	650.2T

Sunshine Net Debt History

	2024	-14.9 M
	2023	-15.6 M
	2022	-17.6 M
	2021	-145.2 K
	2020	923.2 K
	2019	675.1 K
	2018	837.4 K

Other Fundumenentals of Sunshine Biopharma

Net Debt To E B I T D A

Sunshine Biopharma Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Intangible Assets	Net Tangible Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Good Will	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments
Total Assets		1.0	-0.99	-0.94	1.0	0.97	1.0	-0.28	0.35	0.98	0.73	0.76	-0.75	0.57	0.74	-0.73	1.0	0.88	-0.53	1.0	-0.73
Total Stockholder Equity	1.0		-1.0	-0.92	1.0	0.96	1.0	-0.29	0.31	0.99	0.73	0.75	-0.72	0.53	0.71	-0.75	1.0	0.87	-0.55	1.0	-0.75
Net Debt	-0.99	-1.0		0.92	-0.99	-0.96	-1.0	0.29	-0.36	-0.97	-0.7	-0.74	0.72	-0.55	-0.73	0.68	-1.0	-0.86	0.56	-0.99	0.68
Retained Earnings	-0.94	-0.92	0.92		-0.93	-0.97	-0.94	0.21	-0.43	-0.92	-0.81	-0.79	0.9	-0.74	-0.87	0.69	-0.93	-0.94	0.45	-0.95	0.69
Accounts Payable	1.0	1.0	-0.99	-0.93		0.97	1.0	-0.28	0.34	0.98	0.72	0.74	-0.73	0.55	0.72	-0.73	1.0	0.86	-0.54	1.0	-0.73
Total Liab	0.97	0.96	-0.96	-0.97	0.97		0.97	-0.25	0.51	0.93	0.7	0.75	-0.84	0.67	0.8	-0.65	0.97	0.89	-0.42	0.97	-0.65
Total Current Assets	1.0	1.0	-1.0	-0.94	1.0	0.97		-0.28	0.36	0.98	0.72	0.75	-0.75	0.58	0.74	-0.72	1.0	0.88	-0.53	1.0	-0.72
Common Stock	-0.28	-0.29	0.29	0.21	-0.28	-0.25	-0.28		-0.08	-0.27	-0.04	-0.36	0.34	-0.29	-0.33	0.2	-0.28	-0.34	0.29	-0.29	0.2
Short Term Debt	0.35	0.31	-0.36	-0.43	0.34	0.51	0.36	-0.08		0.19	-0.05	0.37	-0.49	0.48	0.54	0.24	0.39	0.39	-0.13	0.36	0.24
Net Receivables	0.98	0.99	-0.97	-0.92	0.98	0.93	0.98	-0.27	0.19		0.8	0.74	-0.72	0.53	0.69	-0.83	0.97	0.86	-0.53	0.98	-0.83
Intangible Assets	0.73	0.73	-0.7	-0.81	0.72	0.7	0.72	-0.04	-0.05	0.8		0.59	-0.69	0.62	0.7	-0.7	0.69	0.73	-0.33	0.73	-0.7
Net Tangible Assets	0.76	0.75	-0.74	-0.79	0.74	0.75	0.75	-0.36	0.37	0.74	0.59		-0.66	0.39	0.69	-0.55	0.75	0.86	-0.7	0.77	-0.55
Property Plant Equipment	-0.75	-0.72	0.72	0.9	-0.73	-0.84	-0.75	0.34	-0.49	-0.72	-0.69	-0.66		-0.91	-0.93	0.54	-0.73	-0.88	0.18	-0.77	0.54
Current Deferred Revenue	0.57	0.53	-0.55	-0.74	0.55	0.67	0.58	-0.29	0.48	0.53	0.62	0.39	-0.91		0.91	-0.3	0.55	0.7	-0.05	0.59	-0.3
Long Term Debt	0.74	0.71	-0.73	-0.87	0.72	0.8	0.74	-0.33	0.54	0.69	0.7	0.69	-0.93	0.91		-0.39	0.73	0.89	-0.32	0.76	-0.39
Good Will	-0.73	-0.75	0.68	0.69	-0.73	-0.65	-0.72	0.2	0.24	-0.83	-0.7	-0.55	0.54	-0.3	-0.39		-0.69	-0.7	0.39	-0.73	1.0
Net Invested Capital	1.0	1.0	-1.0	-0.93	1.0	0.97	1.0	-0.28	0.39	0.97	0.69	0.75	-0.73	0.55	0.73	-0.69		0.87	-0.54	1.0	-0.69
Short Long Term Debt	0.88	0.87	-0.86	-0.94	0.86	0.89	0.88	-0.34	0.39	0.86	0.73	0.86	-0.88	0.7	0.89	-0.7	0.87		-0.5	0.9	-0.7
Capital Stock	-0.53	-0.55	0.56	0.45	-0.54	-0.42	-0.53	0.29	-0.13	-0.53	-0.33	-0.7	0.18	-0.05	-0.32	0.39	-0.54	-0.5		-0.53	0.39
Net Working Capital	1.0	1.0	-0.99	-0.95	1.0	0.97	1.0	-0.29	0.36	0.98	0.73	0.77	-0.77	0.59	0.76	-0.73	1.0	0.9	-0.53		-0.73
Short Term Investments	-0.73	-0.75	0.68	0.69	-0.73	-0.65	-0.72	0.2	0.24	-0.83	-0.7	-0.55	0.54	-0.3	-0.39	1.0	-0.69	-0.7	0.39	-0.73

Click cells to compare fundamentals

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-15.6 M	-14.9 M
Net Debt To EBITDA	4.09	4.29

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sunshine Net Debt from 2010 to 2024

Latest Sunshine Biopharma's Net Debt Growth Pattern

Sunshine Net Debt Regression Statistics

Sunshine Net Debt History

Other Fundumenentals of Sunshine Biopharma

Sunshine Biopharma Net Debt component correlations

About Sunshine Biopharma Financial Statements

Also Currently Popular

Additional Tools for Sunshine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY